Details of the Drug

General Information of Drug (ID: DMOIHWI)

Drug Name
AZD7789
Indication
Disease Entry ICD 11 Status REF
Hodgkin lymphoma 2B30 Phase 2 [1]
Non-small-cell lung cancer 2C25 Phase 2 [2]
Drug Type
Antibody
Cross-matching ID
TTD ID
DNI7E3
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis A virus cellular receptor 2 (TIM3) TT1RWL7 HAVR2_HUMAN Not Available [3]
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hodgkin lymphoma
ICD Disease Classification 2B30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05216835) A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04931654) A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
3 Clinical pipeline report, company report or official report of AstraZeneca